Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma

The central independent review concluded that the NIPU study did not meet the primary endpoint of progression-free survival . However, a statistically significant improvement in PFS for... | June 7, 2023

Related Keywords

Oslo ,Norway ,Germany ,Australia ,Spain ,Bristol Myers Squibbs ,Bristol Myers Squibb ,Halle University ,International Agency For Research On Cancer Globocan ,Professor At Oslo University Hospital ,Oslo University Hospital ,Principal Investigator ,Oslo University ,Carlos De Sousa ,Chief Executive Officer ,International Agency ,Human Leukocyte Antigen ,Ultimovacs Asa Stock Exchange ,News ,Information ,Press Release ,Independent ,Review ,Oncluded ,Hat ,Kid ,Lot ,Feet ,The ,Primary ,Ndpoint ,F ,Survival ,Statistically ,Significant ,Improvement ,N ,Fs Ulti No0010851603 ,